Mobia Medical

Vivistim Paired Vagus Nerve Stimulation (Paired VNS) Therapy is an FDA-approved solution designed to enhance the brain’s ability to remodel in response to functional exercises.

Mobia Medical’s Vivistim Paired VNS Therapy is the first FDA-approved, clinically validated solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments.

Mobia Medical advances solutions to help stroke survivors regain function, independence, and quality of life regardless of time since their stroke.

Mobia Medical aims to improve chronic stroke recovery care, focusing on patients with life-altering motor impairments.

Mobia Medical develops solutions intended to help people with chronic stroke regain function, quality of life and independence, regardless of the time since their stroke.

The company develops recovery solutions for stroke survivors to help them regain function, independence, and quality of life.

Mobia Medical, Inc. lists U.S. patents covering its products, which may also include foreign patents or pending applications.

The company invites inquiries about its services via a contact form.

Mobia Medical accepts inquiries through a contact form and may contact submitters by email. Personal data is processed according to its Privacy Policy.

The company offers Vivistim Paired VNS Therapy, the first FDA-approved, clinically validated solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairment.

The company provides recovery solutions for stroke survivors. Its Vivistim Paired VNS Therapy is clinically validated and FDA-approved for chronic ischemic stroke survivors with moderate to severe upper extremity impairment.

Mobia Medical, Inc. prioritizes privacy for customers, visitors, suppliers, partners, employees, and others.

Mobia Medical, Inc. says it is incorporated in the United States and located at 2802 Flintrock Trace, Suite 226, Austin, TX 78738. The company says it is committed to protecting privacy.

Mobia Medical announces its third quarter 2026 financial results will be released on November 5, 2026. The company, specializing in stroke recovery devices for motor impairments, will host a conference call and webcast at 4:30 p.m. ET to discuss performance and provide an update.

Oct 2026BioSpaceNews article

Mobia Medical’s implantable paired Vagus Nerve Stimulation device is now included in the **2026 guidelines for adult stroke rehabilitation**. The guidelines acknowledge its role in supporting recovery for patients with stroke-related disabilities. The recognition follows clinical validation of the device’s efficacy in improving functional outcomes.

Aug 2026Yahoo FinanceNews article

Mobia Medical (formerly MicroTransponder) rebrands as part of its corporate restructuring. The company specializes in medical transponder technologies for patient monitoring and asset tracking in healthcare settings. This change aligns with its expanded focus on medical applications.

Feb 2026GlobeNewswireNews article

MicroTransponder secures Medicare reimbursement for its **Vivistim®** procedure under **New Technology Ambulatory Payment Classification 1580**, effective January 1, 2026. The procedure now carries a national average payment of **$45,000**, expanding Medicare coverage for the treatment. This change supports broader patient access to the therapy, which targets chronic pain or neurological conditions via implanted transponders.

Nov 2025Yahoo FinanceNews article